European Archives - Page 47 of 1202 - European Medical Journal

Europe Urged to Improve Newborn Biliary Atresia Screening

Biliary atresia is the most common surgical cause of cholestatic jaundice in infants and the leading reason for paediatric liver transplants

Saliva Testing Identifies Early Risk for Cancer and Chronic Diseases

Saliva-based DNA markers could predict cancer, heart disease, and more—offering a non-invasive future for early diagnosis.

AI Enhances Efficiency and Accuracy in Tumour Biomarker Testing

A new study highlights the clinical promise of AI-driven IHC prediction models, showing high accuracy and diagnostic concordance with conventional pathology.

MVA-BN Vaccine Offers Safe Mpox Protection in At-Risk Groups

A German multicentre study shows MVA-BN vaccination is safe and moderately effective in preventing mpox, especially in HIV-negative individuals.

Dupilumab Linked to Increased Psoriasis Risk in Atopic Dermatitis

Given dupilumab’s well-documented benefits in controlling moderate to severe AD, clinicians are advised to weigh this potential risk carefully against its therapeutic advantages.

Widespread Ignorance of Alcohol’s Cancer Risk

Despite alcohol being a leading preventable cause of cancer in the United States, public awareness of its cancer risk remains strikingly low, according to a new study.

Critical Management of Neurocysticercosis with Hydrocephalus

Neurocysticercosis, a parasitic brain infection caused by the larvae of Taenia solium that leads to cysts in the central nervous system…

Minimally Invasive Treatment for Benign Prostatic Hyperplasia

Importantly, 30% mean reductions in prostate volume were sustained up to 18 months post-procedure.

Sun Pharma appoints Richard Ascroft as North American CEO

Ascroft brings more than 30 years of industry experience, including senior roles at Takeda Pharmaceuticals.

Can Microbiome-Guided Therapy Improve Cystic Fibrosis Outcomes?

A new international trial has investigated the safety and efficacy of tailoring antibiotic treatment for cystic fibrosis exacerbations based on sputum microbiome analysis.